VICL

Good News for Vical Cancer Drug Candidate	Vical, Inc. Q4 2009 Earnings Call Transcript	Biotech Deal Activity Takes a Breather
7 Companies in the Race to Find Cures for Cancer	Vical Incorporated Q1 2010 Earnings Call Transcript	Vical Incorporated. Q2 2010 Earnings Call Transcript
Sanofi Failure Opens Door for Aastrom Bio	Bottom Fishing: Any Value in September's Losers?	15 Biotech Stocks With the Lowest Put/Call Ratios
Vical Analyst and Investor Day Transcript	Seven Stocks With CEO Buying in the Past Week	Vical CEO Discusses Q4 2010 Results - Earnings Call Transcript
18 Stocks on the 52 Week Low List Ready to Pop?	Ipilimumab Approval Highlights Active Immunotherapy Renaissance	Vical Is Deeply Undervalued: Technology and Pipeline Offer Upside Reward
Major FDA Approval Could Pave the Way for These 5 Biotechs	Vical: A Biotech Flying Under the Radar	Chinese CEOs: Cook Your Books at Your Own Peril
7 Dirt Cheap Biotech Stocks With Huge Upside	Breakouts: 6 Stocks Showing New Strength	Vical's CEO Discusses Q1 2011 Results - Earnings Call Transcript
4 Biotech Stocks with Extremely Bearish Options Sentiment	Personalized Medicine for the Masses	Careful Analysis Reveals Good Probability of Gains for Vical

Main menu